Improving Access to Healthcare

Despite the remarkable medical progress during the last century, there are still at least 400 million people worldwide who lack access to essential health services1 and more than two billion who cannot afford to buy the medicines they need2. A healthy life, unfortunately, is still far from a given for too many. Every year, eight million people die from cancer3 and 14 million new cases are diagnosed4. Nearly 10 million people develop tuberculosis (TB) annually, including one million children, and the disease claims 1.5 million victims per year5. Nearly half a million people still die of malaria every year6.

As a division of the Novartis Group, Sandoz is committed to playing a key role in achieving global healthcare goals, by pioneering new approaches to drive increased access worldwide. Increasing access to medicine is the basis of our day-to-day business model, but we also run a range of targeted  programs to ensure access for those most in need.

On the following pages, we explain more about the work we do and the programs we run.

  1. Joint WHO/ World Bank news release; http://www.who.int/mediacentre/news/releases/2015/uhc-report/en/
  2. The 2016 Access to Medicine Index. Methodology 2015; http://apps.who.int/medicinedocs/en/m/abstract/Js22176en/
  3. World Health Organization; http://www.who.int/mediacentre/factsheets/fs297/en/
  4. World Cancer Report 2014; http://publications.iarc.fr/Non-Series-Publications/World-Cancer-Reports...
  5. World Health Organization; http://www.who.int/mediacentre/factsheets/fs104/en/

World Health Organization; http://www.who.int/features/factfiles/malaria/en/

 

Ask for Generics

 

 

* Source: 2020 Generic Drug & Biosimilars Access & Savings in the U.S. Report. September 29, 2020.   https://accessiblemeds.org/sites/default/files/2020-09/AAM-2020-Generics...

Access to safe, effective and high-quality generic drugs is vital to the sustainability of the US healthcare system and plays an important role in patient health.

In the past ten years, generics have saved the US $2.2 trillion.1 In 2019 alone, the US generic industry contributed more than $313 billion1 in savings,with Sandoz medicines providing $12.1 billion.2 Generics also improve access for patients to more affordable medicines, accounting for 90 percent of prescriptions filled in the US with an average patient copay of $6.97.1

The core of Sandoz business lies in producing and distributing a broad portfolio of highquality medicines following the loss of their respective patent protection, helping secure substantial savings for patients and health systems and improving access to more affordable treatments. Sandoz is committed to doing its part for patients, healthcare professionals and communities to overcome access challenges, price medicines responsibly and affordably, and deliver increased value across the healthcare system.

1. Source: 2020 Generic Drug & Biosimilars Access & Savings in the U.S. Report. September 29, 2020.  https://accessiblemeds.org/sites/default/files/2020-09/AAM-2020-Generics- Biosimilars-Access-Savings-Report-US-Web.pdf [3]
2. Source: Data on file. Sandoz US Generics Savings 2019. Sandoz Inc. October 2020.

 

The Promise of Biosimilars

As the pioneer and a global leader in biosimilars and the first to bring a biosimilar medicine to the US1, Sandoz is committed to increasing access for patients by bringing high-quality, more affordable, potentially lifechanging biologic treatments to market.

Biosimilars can expand patient access to life-changing biologic medicines, increase healthcare savings and have an important role in creating sustainability for overburdened health systems through increased competition. Cost savings from biosimilar medicines can be used to treat more patients and have the potential to save the US healthcare system $100 billion over 5 years.2

As more biosimilars enter the US market, patients treated with biologic medicines will have access to a broader set of more affordable treatment options. An estimated 1.2 million additional patients will gain access to biologics by 2025 as the result of increasing biosimilar availability.3

Visit the Sandoz Biosimilars section to learn more.

1. Source: US Food and Drug Administration. FDA approves first biosimilar product Zarxio® [press release]; March 6, 2015. https://wayback.archive-it.org/7993/20170111224313/http://www.fda.gov/Ne... [5]. Accessed April 17, 2020.
2. Source: IQVIA Institute for Human Data Science. Biosimilars in the United States 2020–2024 [6]. Published October 6, 2020. Accessed October 7, 2020.
3. Source: The Biosimilars Council. Biosimilars in the United States: Providing More Patients Greater Access to Lifesaving Medicines. Available at: http://biosimilarscouncil.org/wpcontent/ uploads/2019/03/Biosimilars-Council-Patient-Access-Study.pdf [7]. Accessed on April 9, 2020.

Related Links